Literature DB >> 17644138

P21-activated kinase 1: a new molecular marker for intravesical recurrence after transurethral resection of bladder cancer.

Masaaki Ito1, Hiroyuki Nishiyama, Hiroaki Kawanishi, Shigeyuki Matsui, Parry Guilford, Anthony Reeve, Osamu Ogawa.   

Abstract

PURPOSE: It is clinically important to identify bladder cancers with a high risk of intravesical recurrence after transurethral bladder tumor resection. We developed molecular markers for predicting intravesical recurrence of superficial bladder transitional cell carcinoma using oligo-microarray analysis.
MATERIALS AND METHODS: Gene expression profiles associated with intravesical recurrence were analyzed by oligo-microarray in 27 superficial bladder transitional cell carcinoma samples from cases treated with transurethral resection between 2000 and 2004 at Kyoto University Hospital. Of candidate genes the expression of P21-activated kinase (Pak1) was validated by semiquantitative real-time polymerase chain reaction using another set of samples and immunohistochemistry. Furthermore, Pak1 functions in bladder cancer cells were analyzed by the transfection of constitutively active (T423E) or kinase dead (K299R) Pak1.
RESULTS: Microarray identified 25 genes whose expression was associated with recurrence, including Pak1. Pak1 mRNA expression was statistically associated with grade and the risk of recurrence but not with stage in 86 bladder cancers. Immunohistochemistry and multivariate analysis demonstrated that high Pak1 protein expression was an independent factor associated with recurrence (relative risk 2.27, p = 0.008). High Pak1 expression was significantly associated with a high risk of recurrence even in low stage/grade cancers. Transfection with T423E Pak1 into 253J cells progressed cell motility on wound healing assay, whereas transfection with K299R Pak1 decreased EJ cell motility.
CONCLUSIONS: These results suggest that Pak1 expression is associated with recurrence and it might be a useful prognostic marker for superficial bladder transitional cell carcinoma.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17644138     DOI: 10.1016/j.juro.2007.05.012

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  18 in total

Review 1.  PAK1 as a therapeutic target.

Authors:  Julia V Kichina; Anna Goc; Belal Al-Husein; Payaningal R Somanath; Eugene S Kandel
Journal:  Expert Opin Ther Targets       Date:  2010-07       Impact factor: 6.902

2.  PAK1 is a therapeutic target in acute myeloid leukemia and myelodysplastic syndrome.

Authors:  Ashley Pandolfi; Robert F Stanley; Yiting Yu; Boris Bartholdy; Gopichand Pendurti; Kira Gritsman; Jacqueline Boultwood; Jonathan Chernoff; Amit Verma; Ulrich Steidl
Journal:  Blood       Date:  2015-07-13       Impact factor: 22.113

Review 3.  The Rho GTPase signalling pathway in urothelial carcinoma.

Authors:  Solomon L Woldu; Ryan C Hutchinson; Laura-Maria Krabbe; Oner Sanli; Vitaly Margulis
Journal:  Nat Rev Urol       Date:  2017-11-14       Impact factor: 14.432

4.  Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells.

Authors:  Christy C Ong; Adrian M Jubb; Peter M Haverty; Wei Zhou; Victoria Tran; Tom Truong; Helen Turley; Tom O'Brien; Domagoj Vucic; Adrian L Harris; Marcia Belvin; Lori S Friedman; Elizabeth M Blackwood; Hartmut Koeppen; Klaus P Hoeflich
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-11       Impact factor: 11.205

5.  p21-activated kinases in Erbb2-positive breast cancer: A new therapeutic target?

Authors:  Luis E Arias-Romero; Jonathan Chernoff
Journal:  Small GTPases       Date:  2010-09

6.  Clinicopathological and cellular signature of PAK1 in human bladder cancer.

Authors:  Kai Huang; Gang Chen; Jingfang Luo; Youyuan Zhang; Guoxiong Xu
Journal:  Tumour Biol       Date:  2014-11-21

7.  Pak and Rac GTPases promote oncogenic KIT-induced neoplasms.

Authors:  Holly Martin; Raghuveer Singh Mali; Peilin Ma; Anindya Chatterjee; Baskar Ramdas; Emily Sims; Veerendra Munugalavadla; Joydeep Ghosh; Ray R Mattingly; Valeria Visconte; Ramon V Tiu; Cornelis P Vlaar; Suranganie Dharmawardhane; Reuben Kapur
Journal:  J Clin Invest       Date:  2013-09-16       Impact factor: 14.808

8.  Increased Rac1 activity and Pak1 overexpression are associated with lymphovascular invasion and lymph node metastasis of upper urinary tract cancer.

Authors:  Takao Kamai; Hiromichi Shirataki; Kimihiro Nakanishi; Nobutaka Furuya; Tsunehito Kambara; Hideyuki Abe; Tetsunari Oyama; Ken-Ichiro Yoshida
Journal:  BMC Cancer       Date:  2010-04-28       Impact factor: 4.430

9.  Oncogenic activation of Pak1-dependent pathway of macropinocytosis determines BCG entry into bladder cancer cells.

Authors:  Gil Redelman-Sidi; Gopa Iyer; David B Solit; Michael S Glickman
Journal:  Cancer Res       Date:  2013-02-01       Impact factor: 12.701

10.  Overexpression of PAK-1 is an independent predictor of disease recurrence in colorectal carcinoma.

Authors:  Jaudah Al-Maghrabi; Eman Emam; Wafaey Gomaa; Doaa Al-Qaydy; Basim Al-Maghrabi; Abdelbaset Buhmeida; Adel Abuzenadah; Mohammed Al-Qahtani; Mahmoud Al-Ahwal
Journal:  Int J Clin Exp Pathol       Date:  2015-12-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.